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Abstract
Background: Whether seroresponse to a vaccine such as hepatitis B virus (HBV) vaccine can provide a measure of the
functional immune status of HIV-infected persons is unknown.This study evaluated the relationship between HBV vaccine
seroresponses and progression to clinical AIDS or death.
Methods and Findings: From a large HIV cohort, we evaluated those who received HBV vaccine only after HIV diagnosis and
had anti-HBs determination 1–12 months after the last vaccine dose. Non-response and positive response were defined as
anti-HBs ,10 and $10 IU/L, respectively. Participants were followed from date of last vaccination to clinical AIDS, death, or
last visit. Univariate and multivariable risk of progression to clinical AIDS or death were evaluated with Cox regression
models. A total of 795 participants vaccinated from 1986–2010 were included, of which 41% were responders. During 3,872
person-years of observation, 122 AIDS or death events occurred (53% after 1995). Twenty-two percent of non-responders
experienced clinical AIDS or death compared with 5% of responders (p,0.001). Non-response to HBV vaccine was
associated with a greater than 2-fold increased risk of clinical AIDS or death (HR 2.47; 95% CI, 1.38–4.43) compared with a
positive response, after adjusting for CD4 count, HIV viral load, HAART use, and delayed type hypersensitivity skin test
responses (an in vivo marker of cell-mediated immunity). This association remained evident among those with CD4 count
$500 cells/mm
3 (HR 3.40; 95% CI, 1.39–8.32).
Conclusions: HBV vaccine responses may have utility in assessing functional immune status and risk stratificating HIV-
infected individuals, including those with CD4 count $500 cells/mm
3.
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Introduction
Infection with HIV-1 is unsparing, resulting in perturbations in
nearly every immune cell type and immune response. How these
impairments coalesce to alter immune responses in vivo and result
in progressive immune depletion and eventually acquired immune
definiciency syndrome (AIDS) in untreated HIV-infected persons
is unknown. Although CD4 cell count and plasma HIV viral load
(VL) are commonly used to assess HIV disease stage [1,2,3], they
may not provide a complete measure of the functional immuno-
logical status of an HIV-infected person, despite receipt of therapy.
For example, in the SILCAAT and ESPRIT clinical trials, which
evaluated the use of interleukin-2 (IL-2) in subjects receiving highly
active antiretroviral therapy (HAART), simply having a higher
CD4 cell count as the result of IL-2 treatment did not correspond
to a lower risk of experiencing opportunistic disease or death from
any cause, suggesting that a greater number of CD4 lymphocytes
did not necessarily equate with reconstitution of immune function
[4]. Regarding the relationship between CD4 cell counts and VL,
Rodriguez, et al. demonstrated that VL predicted less than 10% of
observed CD4 cell loss, and others have demonstrated that VL
explained less than 5% and 12% of the variability in the rate of
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other parameters reflective of immune function, such as responses
to vaccines, may serve as important immunological tools to
identify subsets of HIV-infected subjects who manifest functional
impairment in the immune system, despite high CD4 cell counts
or low VL before or after receipt of HAART.
Although not a vaccine in the traditional sense, immune system
function in HIV-infected individuals has been probed by eliciting
delayed-type hypersensitivity (DTH) skin test reactivity to recall
antigens such as candida, mumps, trichophyton, and tetanus
toxoid. DTH responses are a strong in vivo parameter of cell-
mediated immunity (CMI) and predict risk of AIDS, independent
of the CD4 count and VL [7,8,9,10,11,12]. Investigations in the
pre-HAART era within the U.S. military were among the first to
establish the validity of cutaneous DTH testing in predicting AIDS
progression and staging disease by categorizing DTH responses by
the number of positive skin tests [9,11]. More recently, poor DTH
responses have been associated with increased risk of AIDS or
death in women receiving HAART [10], and with reduced CD4
cell count reconstitution after HAART initiation [13]. However,
despite its potential utility, DTH responses have not been
recommended in the clinical setting for several years [14].
One vaccine used commonly in patients with HIV infection is
hepatitis B virus (HBV) vaccine [15]. Unlike other vaccines used
frequently in HIV-infected patients, such as pneumococcal
polysaccharide, tetanus toxoid, and influenza vaccines, assessment
of HBV vaccine serologic responses in HIV-infected adults is now
recommended by guidelines [1]. Additionally, tests to evaluate
serologic responses to HBV vaccine are widely available.
Furthermore, as a peptide antigen administered intramuscularly,
the development of an antibody response following HBV
vaccination requires T-cell help, and is also reflective of other
aspects of immune function including antigen presentation, and B-
cell function [16,17,18,19]. Therefore, unlike pneumococcal
polysaccharide vaccine which is a T-cell independent antigen,
HBV vaccine may provide a more complete assessment of B- and
T-cell immune function for an HIV-infected individual compared
with some of the other vaccines.
While functional responses to both recall and neoantigens have
been previously associated with factors known to predict HIV-
related disease progression [20], the possible association between
HBV vaccine responses and disease progression has been
investigated in only one previous study [21]. In that investigation,
vaccine responders were less likely to develop persistent general-
ized lymphadenopathy than non-responders, but firm conclusions
were limited as the study included 27 individuals from the pre-
HAART era. Therefore, in the current study we sought to
evaluate whether HBV vaccine antibody responses predicted the
risk of progression to AIDS or death indepdendent of CD4 cell
counts, VL, DTH responses, and HAART use in those immunized
after HIV diagnosis in a large well-characterized cohort of HIV-
infected indivduals.
Methods
Study population
The U.S. Military HIV Natural History Study (NHS) is an
ongoing, continuous enrollment observational cohort of HIV-
infected Department of Defense beneficiaries followed at seven
military medical centers in the United States. The comprehensive
epidemiology of HBV infection, the effectiveness of HBV
vaccination, and factors associated with HBV vaccine responses
in this large prospectively followed, continuously enrolling cohort
have all been previously described [15,22,23,24,25]. All adult
DoD beneficiaries with a diagnosis of HIV infection followed at a
participating site and ability to provide written, informed consent
are eligible for participation. Following enrollment patients are
seen every six months. Data collected includes demographic
information, past and interim medical histories and illnesses,
medications, vaccinations, and standard clinical laboratory studies,
and for those that died, dates of death. HIV exposure category is
not routinely captured, however rates of HIV risk behaviors have
been previously reported and intravenous drug use is rare (,3%)
[26].
Ethics Statement
All NHS participants provided written, informed consent, anda
pproval for this research was obtained from the Uniformed
Services University of the Health Sciences Infectious Disease
Institutional Review Board.
Participant eligibility and definitions
NHS participants were eligible for the current analysis if (1) they
were concurrently non-reactive for HBsAg and HBcAb initially
following HIV diagnosis, (2) there was a documented date of HBV
vaccination after the HIV seropositivity date, and (3) there was a
documented hepatitis B virus surface antibody (anti-HBs)
measurement 1–12 months after the last dose of vaccine.
Participants with a history of HBV vaccination prior to HIV
seropositivity were excluded. Individuals were classified as vaccine
non-responders (anti-HBs,10 IU/L) or responders (anti-
HBs$10 IU/L) for statistical analyses using the results obtained
from commercially available assays utilized at each NHS study
site. For individuals without a documented vaccine response,
serum repository samples were tested for anti-HBs as previously
described [15]. Neither the HBV vaccine dose nor the commercial
formulation was captured in the database. The presence of an
AIDS-defining illness was defined using 1993 Centers for Disease
Control and Prevention criteria [27], with the exception of isolated
CD4 cell count ,200 cells/mm
3. DTH skin test responses were
assessed and categorized similar to previous investigations by the
number of positive skin tests: normal response (the presence of 2 or
more positive skin tests), partial anergic response (one positive skin
test), and complete anergic response (zero positive skin tests)
[9,11]. HAART was defined as combination antiretroviral therapy
with at least three agents from two different drug classes, or the
triple nucleoside combination of zidovudine, lamivudine, and
abacavir. An HIV seroconverter was defined as an individual with
a documented HIV negative screening test followed by reactive
screening and confirmatory HIV tests within 5 years.
Study design and statistical methods
Descriptive statistics were used to examine the characteristics of
vaccine responders and non-responders at the time of last HBV
vaccination. Medians were reported with inter-quartile ranges
(IQR). Proportions were compared with chi-square or Fisher’s
exact tests; continuous valued variables were compared with
general linear models or Kruskal-Wallis tests as appropriate. The
number of initial AIDS or death events and the total number of
AIDS or death events were summarized for vaccine non-
responders and responders. For analyses regarding rates or risk
of AIDS or death, follow-up time started on the date of last HBV
vaccination. The primary endpoint was the first of an AIDS-
defining illness or death within 18 months after the last NHS study
visit. Those who did not experience an endpoint were censored at
the last NHS study visit. Rates for the primary endpoint were
calculated per 100 person-years of follow-up (PY) for vaccine
responders and non-responders overall, and for subgroups formed
HBV Vaccine Responses and AIDS/Death
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response, and HAART use at the time of last HBV vaccination,
and were compared using rate ratios (RR) from Poisson regression.
Rates were also calculated for death separately. Univariate and
multivariable Cox proportional hazard models were used to
evaluate the association of covariates at the time of last HBV
vaccination with subsequent development of clinical AIDS or
death. All models were stratified by era of HIV diagnosis
according to when HAART was introduced into clinical care
(i.e., prior to 1996 versus 1996 or later); multivariable models were
also adjusted for duration of HIV infection at the time of last HBV
vaccination and HIV seroconverter status. Preliminary multivar-
iable models included all baseline covariates associated with
clinical AIDS or death with p,0.10. Covariates no longer found to
be significantly associated with the primary endpoint were then
removed in stepwise fashion to derive the final multivariable
model. The final model was also repeated for death separately.
Two sensitivity analyses were performed for the compound
primary endpoint. First, to eliminate confounding due to the use
of HAART, analyses were repeated with censoring at the time of
HAART initiation. Second, to assess whether HBV vaccine
response was associated with AIDS or death among those with
high CD4 cell counts, another analysis was done for the subgroup
of participants with CD4 cell count $500 cells/mm
3 at the time of
last HBV vaccination. Hazard ratios (HR) were reported with
95% confidence intervals (CI). All p-values were two-sided with
p,0.05 considered statistically significant. No adjustments were
made for multiple comparisons. All statistical analyses were
performed using SAS software (version 9.1, Cary, NC).
Results
Participant characteristics
Seven hundred ninety-five participants met study criteria, and
of these, 322 (41%) were vaccine responders. (Table 1) The date of
administration of the last dose of vaccine was between 1986 to
2010. The median time from HIV seropositivity to receipt of the
last HBV vaccination was 2.7 years (IQR, 1.1–6.1). Thirty-nine
percent (n=310) were on HAART at the time of last vaccination.
Of participants not on HAART at last vaccination, 74 (46%)
responders and 136 (42%) non-responders started HAART after
last vaccination, but prior to censoring (p=0.31). Overall, the
median CD4 count was 509 cells/mm
3 (IQR, 372–668) at last
vaccination. The median nadir CD4 cell count prior to last
Table 1. Participant characteristics overall and by vaccine response at the time of last hepatitis B vaccination.
Vaccine Response
Characteristic N Overall
Anti-HBs,10 IU/L
(N=473)
Anti-HBs$10 IU/L
(N=322) P
Age, median (IQR) years 795 32.1 (27.2–38.2) 31.6 (27.5–37.9) 32.4 (26.9–38.3) 0.70
Male gender 795 695 (87) 422 (89) 273 (85) 0.06
Ethnicity 795 0.69
Caucasian 360 (45) 220 (47) 140 (44)
African American 315 (40) 184 (39) 131 (41)
Other 120 (15) 69 (15) 51 (16)
Year of HIV diagnosis, median (IQR) 795 1994 (1990–1999) 1992 (1989–1998) 1996 (1992–2001) ,0.001
Year of last HBV vaccination, median (IQR) 1999 (1993–2004) 1997 (1993–2002) 2001 (1997–2006) ,0.001
Years from HIV diagnosis to last HBV
vaccination, median (IQR) years
795 2.7 (1.1–6.1) 2.6 (1.1–5.9) 2.9 (1.1–6.4) 0.29
Anti-HCV positive 778 14 (2) 7 (2) 7 (2) 0.58
Number of vaccinations 795 0.004
1–2 308 (39) 201 (43) 107 (33)
3 269 (34) 161 (34) 108 (34)
4–6 187 (24) 99 (21) 88 (27)
$7 31 (4) 12 (3) 19 (6)
CD4 count, median (IQR) cells/mm
3 754 509 (372–668) 455 (326–618) 582 (433–746) ,0.001
Nadir CD4 count, median (IQR) cells/mm
3 697 352 (243–489) 340 (224–475) 376 (261–499) 0.03
Viral load, median (IQR) log10 copies/mL 577 3.0 (1.4–4.1) 3.5 (2.1–4.3) 2.3 (1.4–3.9) ,0.001
Prior AIDS-defining illness 795 45 (6) 28 (6) 17 (5) 0.70
DTH Response 795 0.02
Normal 317 (40) 203 (43) 114 (35)
Partial anergy 65 (8) 45 (10) 20 (6)
Complete anergy 43 (5) 26 (6) 17 (5)
Unknown 370 (47) 199 (42) 171 (53)
Taking HAART 795 310 (39) 147 (31) 163 (51) ,0.001
NOTE. Data are no. of participants (%) with data available, unless otherwise indicated. IQR, inter-quartile range; Anti-HBs, hepatitis B surface antibody; HCV, hepatitis C
virus; DTH, delayed-type hypersensitivity; HAART, highly active antiretroviral therapy.
doi:10.1371/journal.pone.0033488.t001
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3 (IQR, 243–489). Sixty-one percent
of vaccinees received $3 doses of vaccine. Median VL at the time
of last HBV vaccination was 3.0 log10 copies/mL (IQR, 1.4–4.1).
VL at the time of last vaccination was unknown for 217 (27%) of
those included in the study, as this test was not clinically available
prior to 1996 when some study participants received HBV
vaccination. Cutaneous DTH response at last vaccination was
normal for 317 (40%), and unknown for 370 (47%) as this test was
not performed at all study sites.
Follow-up, outcomes, and rates of events
During a total of 3,872 person-years of observation, 105 (22%)
non-responders and 17 (5%) responders experienced a clinical
AIDS or death event (p,0.001) (Table 2). Of the total 122 initial
AIDS or death events, 65 (53%) occurred during 1996 or later.
Sixty-seven (14%) non-responders and 11 (3%) responders died
during study follow-up (p,0.001). The most common AIDS events
other than death were Pneumocystis jiroveci pneumonia, candidiasis,
wasting, Mycobacterium avium complex infection and Kaposi
sarcoma. Fifty (11%) non-responders had multiple events,
compared with 8 (3%) responders (p,0.001).
Overall, the unadjusted rate for experiencing an initial AIDS or
death event was 4.7 (95% CI, 3.9–5.7) per 100 PY for non-
responders compared with 1.0 (95% CI, 0.6–1.7) per 100 PY for
responders (p,0.001 for the rate ratio comparison). For death
events, the rates (95% CI) per 100 PY were 3.4 (2.8–4.1) per 100
PY for non-responders and 0.8 (0.4–1.3) per 100 PY for
responders (p,0.001). When evaluating rates of the composite
end-point of first AIDS or death event within subgroups defined
by number of HBV vaccine doses, DTH response, HAART use,
CD4 cell count and VL categories at last HBV vaccination, non-
responders had significantly higher rates of AIDS or death
compared to responders in almost every subgroup (Table 3).
The highest rates were seen in non-responders who were also
completely anergic (10.1 per 100 PY), those with CD4 cell count
,350 at last HBV vaccination (10.6 per 100 PY), those with
Table 2. Number (%) of first AIDS or death events and follow-up time by vaccine response status.
Anti-HBs,10 IU/L (N=473) Anti-HBs$10 IU/L (N=322) P
Sequence of initial event type, N (%) ,0.001
No event 368 (77.8) 305 (94.7)
AIDS 38 (8.0) 6 (1.9)
AIDS then death 41 (8.9) 6 (1.9)
Death 26 (5.5) 5 (1.6)
Initial AIDS event by type, N
Pneumocystis jiroveci pneumonia 15 2
Candidiasis 14 3
Wasting 90
Mycobacterium avium-complex infection 70
Kaposi sarcoma 70
Non-Hodgkin’s lymphoma 41
Cryptosporidiosis 40
AIDS-related dementia 30
Cryptococcosis 31
Pneumonia 30
Cytomegalovirus disease 22
Toxoplasmosis 21
Progressive multifocal leukoencephalopathy 20
Herpes simplex virus 20
Mycobacterium tuberculosis 11
Histoplasmosis 10
Coccidiomycosis 01
Total number of events per person, N (%) ,0.001
0 368 (77.8) 305 (94.7)
1 55 (11.6) 9 (2.8)
2 23 (4.9) 6 (1.9)
3 13 (2.8) 1 (0.3)
4 or more 14 (3.0) 1 (0.3)
Follow-up time
Total years 2,236 1,636
Median (IQR) years 3.5 (1.6–6.5) 3.8 (1.7–7.3)
NOTE. Anti-HBs, hepatitis B surface antibody.
doi:10.1371/journal.pone.0033488.t002
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and those who were not on HAART at last HBV vaccination (6.4
per 100 PY). Although the rates of AIDS or death were low for
both non-responders and responders who were also on HAART at
last vaccination (1.0 and 0.4 per 100 PY, respectively), even among
these participants there was a trend for better outcomes in
responders (p=0.21).
Univariate and multivariate risk of clinical AIDS or death
In univariate analysis, those with non-response to HBV vaccine
had a 4-fold increased risk of AIDS or death following the last dose
of vaccine compared with those who did respond (HR 4.01; 95%
CI 2.37–6.80) (Table 4). Other factors at last vaccination which
were associated with increased risk of AIDS or death included
lower CD4 cell count at the time of last vaccination, lower nadir
CD4 cell count prior to last vaccination, higher or unknown VL at
last vaccination, partial or complete anergic DTH response, and
not being on HAART at the time of last HBV vaccination.
In the final multivariable model for risk of initial AIDS or death
event (stratified by HIV diagnosis era and adjusted for HIV
seroconversion status and duration of HIV infection prior to last
vaccination), having a hepatitis B vaccine non-response was
independently associated with a greater than 2-fold increased risk
of progression to AIDS or death (HR 2.47; 95% CI, 1.38–4.43)
(Table 5; Model 1). Lower CD4 cell count, not being on HAART,
higher VL, and partial and complete anergic DTH response all
remained associated with an increased risk of AIDS or death. The
number of HBV vaccinations and nadir CD4 cell count prior to
last vaccination were not included in the final multivariable model
because they were not significantly associated with risk of AIDS or
death in preliminary multivariable models. Having a non-response
to HBV vaccine remained significantly associated with increased
risk of AIDS or death in the two sensitivity analyses: with
censoring at HAART initiation (Model 2 HR, 3.22; 95% CI,
1.36–7.66); and for the subset of participants with CD4 count
$500 cells/mm
3 at time of last HBV vaccination (Model 3 HR,
3.40; 95% CI, 1.39–8.32).
Discussion
We sought to identify a clinically-relevant and easily measured
parameter that may give insights into the status of the functionality
of the immune system in HIV-infected persons that is independent
of the contemporary means used to assess HIV disease stage,
namely absolute CD4 T-cell counts. The results of this study
indicate that among HIV-infected individuals who receive HBV
vaccine after HIV diagnosis, the overall rate of experiencing an
initial AIDS or death event was approximately 4-fold higher in
vaccine non-responders than responders. Additionally, in a
multivariable model, non-response to the vaccine characterized
as an anti-HBs of ,10 IU/L independently predicted a nearly
2.5-fold increase in the risk of developing clinical AIDS or death.
Notably, this association was independent of CD4 cell count, VL,
HAART use, duration of HIV infection, HIV seroconversion
status, and the previously used marker of immune function,
cutaneous DTH to recall antigens. Consistent with these
observations, the event rates were significantly different between
HBV vaccine non-responders and responders in those with CD4
cell count $500 cells/mm
3 or with normal DTH responses.
Collectively, these data indicate that the antibody response to
HBV vaccine is tracking a unique aspect of immune function that
cannot be optimally captured by assessment of CD4, VL or DTH
Table 3. Rates for first event of clinical AIDS or death per 100 person-years of follow-up by hepatitis B vaccine response for CD4
cell count, viral load, delayed-typy hypersensitivity response, and highly active antiretroviral therapy subgroups.
Subgroup Anti-HBs,10 IU/L Rate (95% CI) Anti-HBs$10 IU/L Rate (95% CI) Rate Rato (95% CI) P
Number of HBV vaccine doses
1–2 5.6 (4.2–7.5) 2.0 (1.1–3.7) 2.8 (1.4–5.5) ,0.01
$3 4.2 (3.3–5.4) 0.6 (0.3–1.3) 6.8 (3.1–14.9) ,0.001
CD4 count, cells/mm
3
,350 10.6 (8.1–13.8) 2.7 (1.1–6.4) 4.0 (1.6–9.9) ,0.01
350–500 3.2 (2.1–4.8) 0.9 (0.3–2.7) 3.7 (1.1–12.5) 0.03
$500 2.6 (1.7–3.9) 0.7 (0.3–1.4) 3.8 (1.6–8.8) ,0.01
Viral load, copies/mL
#400 0.7 (0.3–1.9) 0.0 (0.0- --) --- 1.0
.400 3.9 (2.8–5.4) 1.6 (0.8–3.1) 2.4 (1.2–5.0) 0.02
Unknown 8.6 (6.7–10.9) 2.0 (1.0–4.1) 4.2 (2.0–8.8) ,0.001
DTH Response
Normal 4.1 (3.1–5.4) 1.0 (0.5–2.0) 4.1 (2.0–8.7) ,0.001
Partial anergy 8.4 (5.2–13.6) 2.4 (0.8–7.6) 3.5 (1.0–11.8) 0.048
Complete anergy 10.1 (5.6–18.2) 0.9 (0.1–6.7) 10.8 (1.4–83.3) 0.02
Unknown 3.9 (2.7–5.6) 0.8 (0.3–2.0) 4.6 (1.8–12.0) ,0.01
Taking HAART
No 6.4 (5.2–7.8) 1.5 (0.9–2.6) 4.2 (2.4–7.3) ,0.001
Yes 1.0 (0.5–2.1) 0.4 (0.1–1.3) 2.4 (0.6–9.2) 0.21
Overall 4.7 (3.9–5.7) 1.0 (0.6–1.7) 4.5 (2.7–7.5) ,0.001
NOTE. CI, confidence interval; Anti-HBs, hepatitis B surface antibody; DTH, delayed-type hypersensitivity; HAART, highly active antiretroviral therapy.
doi:10.1371/journal.pone.0033488.t003
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serves as an independent prognosticator of clinical outcome in
HIV infected persons, it may have clinical utility in the risk
stratification of HIV-infected persons, including those with CD4
cell count $500 cells/mm
3. Finally, as HBV vaccine responses
predicted risk of AIDS or death independent of VL these results
Table 4. Univariate analysis for factors at the time of last hepatitis B vaccination associated with risk of first clinical AIDS or death
event, stratified by HIV diagnosis era (pre-1996 versus 1996 or later).
Characteristic N Number of Events Univariate HR (95% CI) P
Age, per 10 year increase 795 0.91 (0.72–1.16) 0.45
Gender
Male 695 109 1.44 (0.81–2.57) 0.21
Female 100 13 Referent
Ethnicity
Caucasian 360 61 Referent
African American 315 44 0.71 (0.48–1.05) 0.09
Other 120 17 0.81 (0.47–1.39) 0.44
Duration of HIV infection, months
,18 340 40 Referent
18–24 147 29 1.45 (0.90–2.35) 0.13
.24 308 53 1.21 (0.79–1.84) 0.38
Anti-HCV positive
No 764 115 Referent
Yes 14 1 0.90 (0.13, 6.45) 0.91
Total no. HBV vaccinations
1–2 308 55 1.42 (1.00, 2.04) 0.05
$3 487 67 Referent
CD4 count, cells/mm
3
,200 47 26 6.88 (4.15–11.42) ,0.001
200–499 316 59 2.03 (1.34–3.06) ,0.001
$500 391 31 Referent
Nadir CD4 count, cells/mm
3
,350 343 68 1.83 (1.28–2.63) ,0.01
$350 354 54 Referent
Viral load, copies/mL
#400 262 4 Referent
.400 315 45 8.15 (2.92–22.69) ,0.001
Unknown 218 73 12.29 (4.43–34.14) ,0.001
Prior AIDS-defining illness
No 750 112 Referent
Yes 45 10 1.58 (0.83–3.03) 0.17
DTH Response
Normal 317 58 Referent
Partial anergy 65 20 2.10 (1.26–3.50) ,0.01
Complete anergy 43 12 2.50 (1.34–4.67) ,0.01
Unknown 370 32 1.10 (0.71–1.71) 0.68
Taking HAART
No 485 112 Referent
Yes 310 10 0.21 (0.11–0.40) ,0.001
Anti-HBs Response, IU/L
,10 473 105 4.01 (2.37–6.80) ,0.001
$10 322 17 Referent
NOTE. N, number of participants with data available; HR, hazard ratio; CI, confidence interval; Anti-HBs, hepatitis B surface antibody; HCV, hepatitis C virus; DTH, delayed-
type hypersensitivity; HAART, highly active antiretroviral therapy.
doi:10.1371/journal.pone.0033488.t004
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HIV disease outcomes.
The exact mechanisms responsible for non-response to hepatitis
B vaccine in HIV-infected individuals are not entirely known.
Conceivably, the genetic and immune factors which underlie the
non-response to HBV vaccine in HIV-uninfected persons are also
present in those with HIV [17,19,28,29,30]. However, in HIV-
infected adults, additional mechanisms may be operative as the
rate of non-responsiveness to HBV vaccine is significantly greater.
In viremic HIV-infected individuals the interaction between CD40
ligand on CD4 T-cells and CD40 on B-cells (a key interaction for
HBV vaccine responsiveness [19]) is impaired [31,32]. This
reduction in helper T-cell function may at least partially explain
the poor HBV vaccine responses observed in those with detectable
VL. However, this T- and B-cell interaction appears to normalize
following HAART [31]. Therefore, the persistently poor HBV
vaccine responses seen in those on suppressive HAART [25]
suggest that other aspects of immune function required for a
response to HBV vaccine remain abnormal in aviremic individ-
uals. Increased CD4 T-cell activation was associated with reduced
responses to HBV vaccine and other similar neoantigens in
subjects receiving HAART [20,33]. Additionally, non-response to
HBV vaccine in HIV-infected individuals was found to be
significantly associated with an increased proportion of regulatory
T( T reg) cells [34]. Treg cells have also been associated with non-
response to HBV immunization and other vaccines in HIV-
uninfected adults [35,36]. Lastly, HBV vaccine non-response may
reflect increased underlying immune senescence, which has also
been associated with lack of responsiveness to other vaccines in
healthy and HIV-infected adults [37,38,39,40].
While the mechanisms discussed above may explain the poor
response rates to HBV vaccine in HIV-infected individuals, it is
unclear which mechanism(s) may be specifically associated with
the risk of AIDS or death. Decreased CMI is the hallmark of HIV-
associated immune dysfunction [20], and responses to HBV
vaccine are dependent on T-cell help [18,19], but we found HBV
vaccine responses were associated with the risk of AIDS/death
independent of CD4 cell count, and a marker of CMI, DTH
responses [9,10]. Furthermore, the independent association
between HBV vaccine responses and AIDS/death was observed
in the subset of those with CD4 count $500 cells/mm
3. Thus,
facets of immune function other than CMI (as assessed by DTH)
may also be associated with worse HIV clinical outcomes, and
such aspects of immune dysfunction appear to be evident in those
with relatively high CD4 cell counts. Immune activation has
clearly been associated with HIV progression [41], so perhaps
non-response to HBV vaccine serves as a marker of immune
activation. Alterations in B-cell function are also well described in
Table 5. Multivariate models for factors associated with risk of first clinical AIDS or death event.
Model 1-Overall
1
Model 2- Censored at
HAART Initiation
2
Model 3- CD4$500 at Last HBV
Vaccination
3
Characteristic Multivariate HR (95% CI) P Multivariate HR (95% CI) P Multivariate HR (95% CI) P
Ethnicity
Caucasian Referent Referent Referent
African American 0.61 (0.40–0.91) 0.02 0.62 (0.38–1.01) 0.05 0.67 (0.31–1.48) 0.32
Other 0.59 (0.33–1.06) 0.08 0.51 (0.26–0.98) 0.04 0.52 (0.14–1.96) 0.33
CD4 cell count, per 50 cells/
mm
3 increase
0.87 (0.83–0.92) ,0.001 0.83 (0.77–0.88) ,0.001 N/A
Viral load, copies/mL
#400 Referent ND
4 Referent
.400 3.09 (1.03–9.25) 0.04 11.59 (1.22–109.9) 0.03
Unknown 4.45 (1.42–13.96) 0.01 10.44 (1.00–109.1) 0.05
DTH Response
Normal Referent Referent Referent
Partial anergy 1.77 (1.04–3.01) 0.04 2.44 (1.30–4.56) ,0.01 1.37 (0.39–4.74) 0.62
Complete anergy 3.05 (1.56–5.96) ,0.01 4.74 (2.35–9.53) ,0.001 3.31 (0.36–30.45) 0.29
Unknown 1.28 (0.78–2.09) 0.34 1.38 (0.79–2.44) 0.26 1.41 (0.50–3.94) 0.52
Taking HAART
No Referent N/A Referent
Yes 0.27 (0.12–0.61) ,0.01 1.18 (0.15–9.43) 0.88
Anti-HBs Response, IU/L
,10 2.47 (1.38–4.43) ,0.01 3.22 (1.36–7.66) ,0.01 3.40 (1.39–8.32) ,0.01
$10 Referent Referent Referent
1Model 1 (Overall) includes 754 people with 116 events.
2Model 2 (Censored at HAART initiation) included 425 participants with 83 events.
3Model 3 (CD4 $500 at last HBV vaccination) included 391 participants with 31 events.
4Viral load was not included in Model 2 because there were no events in the 23 participants with viral load #400 copies/mL.
NOTE. HR, hazard ratio; CI, confidence interval; DTH, delayed type hypersensitivity; HAART, highly active antiretroviral therapy; Anti-HBs, hepatitis B surface antibody;
ND, not done; N/A, not applicable. All three models were adjusted for duration of HIV infection at the time of last vaccination (per 6 months), and known HIV
seroconversion status. Models 1 and 3 were also stratified for HIV diagnosis era (pre-1996 versus 1996 or later).
doi:10.1371/journal.pone.0033488.t005
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such impairments are associated with the risk of AIDS or death is
not known. Lastly, while the complete role of Treg cells in HIV
pathogenesis and vaccine responsiveness remains undefined [35],
immune senescence has been associated with more advanced HIV
infection [37] and increased risk of death in non-HIV-infected
individuals [42]. Therefore, further investigation of the mecha-
nisms responsible for non-response to HBV vaccine may yield
additional insights on aspects of immune function that are
associated with clinical outcomes and which remain persistently
abnormal or are restored following HAART.
One potential criticism of the current study may be that it
included those that received less than the recommended three
doses of HBV vaccine. We chose to include those with 1–2 doses of
vaccine with the rationale that those who were able to respond to
one or two doses of vaccine may have similar, or even better,
immune function than those who responded only after 3 or more
doses. The profound difference in the rates of AIDS or death for
responders and non-responders observed in those with either 1–2
or $3 doses (Table 3) suggest inclusion of those with less than 3
doses did not confound the results. Additionally, the number of
vaccine doses was not associated with the risk of AIDS or death in
preliminary multivariate Cox regression models, so it was not
included in the final models. Another criticism may be that we
used too wide of a window (1–12 months) to characterize vaccine
response, allowing some responders to wane, thus introducing
misclassification bias. While this is possible, such bias would only
favor the null hypothesis, thus the difference in outcomes we
observed is likely valid.
There were additional limitations to the current study. The HIV
cohort analyzed in this study is distinct in some aspects when
compared with other large HIV cohorts which may limit
generalizability of the findings. Such characteristics include
enrollment early after HIV infection due to military HIV
screening, open access to care in the military health system, and
virtually no intravenous drug use [26]. However, these character-
istics should only minimize confounding from drug use or
differences in access to care, both of which can impact HIV
outcomes [43]. The current study does not apply to all HIV-
infected individuals. Many patients with HIV infection do not
receive HBV vaccine, as approximately 50% may already be HBV
infected at the time of HIV diagnosis [22]. Additionally, an
increasing proportion of newly diagnosed HIV patients have
received HBV vaccine prior to HIV infection [24]. Additionally,
the results of the current study may have been confounded as the
majority of non-responders were vaccinated in the pre-HAART
era, whereas, a higher proportion of responders were vaccinated in
the HAART era and receiving HAART at the time of last
vaccination. However, the consistency of the results from
multivariable models adjusting for era of HIV diagnosis, and
HAART use, with the sub-group analysis of patients not receiving
HAART suggests that such confounding, if present, was minimal
and did not diminish the overall study conclusions. Finally, VL
and DTH responses were not available for all participants, and few
events occurred in those on HAART and with VL#400 copies/
mL.
In conclusion, the antibody response to HBV vaccine may
provide a measure of immune status that cannot be fully captured
by assessment of the CD4 count, VL or DTH skin test responses,
and as such, may serve as a tool for risk stratification of HIV-
infected persons, including those with relatively preserved CD4
cell count. Understanding the reasons for HBV non-response in
those with HIV may provide new insights into immune
dysfunction during HIV, as well as result in the development of
new immune-based therapies.
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